Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhoenix Group Holdings Regulatory News (PHNX)

  • There is currently no data for PHNX

Strategic Investor Update

28 Jan 2022 07:09

RNS Number : 9647Z
Phoenix Group Holdings PLC
28 January 2022
 

LEI: 2138001P49OLAEU33T68

 

Strategic investor update

 

Phoenix Group Holdings plc ("Phoenix" or "the Group") notes that abrdn plc ("abrdn") has today announced the successful sale of approximately 40 million shares in Phoenix, representing approximately 4% of Phoenix's total issued share capital. The sale was effected by way of an accelerated bookbuild to a range of institutional investors ("the Placing"). abrdn has announced that it intends to return the net proceeds of the Placing to its shareholders.

 

Following the settlement of the transaction, abrdn's holding in Phoenix will be approximately 10.4% of Phoenix's total issued share capital. Importantly, with abrdn's holding remaining in excess of 10%, the two parties' Relationship Agreement will remain in place which entitles it to appoint a director to the Phoenix Board.

 

abrdn continues to be Phoenix's core strategic asset management partner and manages c.£165 billion of the Group's assets under administration.

 

Stephen Bird, CEO of abrdn, commented on the placing:

 

"Our strategic partnership with Phoenix remains very important to us. This was further evidenced by the simplified and extended relationship we announced in February 2021.

 

We have therefore reconfirmed our commitment to our remaining 10.4% shareholding in Phoenix which retains our right to appoint a director to the Phoenix Board."

 

Phoenix's other strategic investor, MS&AD Insurance Group Holdings, Inc. ("MS&AD"), continues to retain a 14.5% shareholding. MS&AD highly values the strategic relationship and shareholding in Phoenix. Its holding remains a key part of MS&AD's long-term strategy to diversify its earnings internationally and MS&AD expects to remain a significant shareholder.

 

-------------------------------------------------------------------------------------------------------------------------------------------------------

Enquiries

Investors/analysts:

Claire Hawkins, Director of Corporate Affairs, Phoenix Group

+44 (0)20 3735 0575

Andrew Downey, Investor Relations Director, Phoenix Group

+44 (0)20 3735 0160

Media:

Douglas Campbell, Teneo

+44 (0)775 313 6628

Shellie Wells, Corporate Communications Director, Phoenix Group

+44 (0)20 3735 0922

-------------------------------------------------------------------------------------------------------------------------------------------------------

Legal Disclaimers

This announcement in relation to Phoenix and its subsidiaries (the "Group") contains forward-looking statements about the Group's current plans, goals and expectations relating to future financial events, conditions, performance, results, strategy and/or objectives. Statements containing the words: 'believes', 'intends', 'will', 'expects', 'may', 'should', 'plans', 'aims', 'seeks', 'continues', 'targets' and 'anticipates' or other words of similar meaning are forward-looking. Such forward-looking statements involve risk and uncertainty because they relate to future events and circumstances that are beyond the Group's control. As a result, such future events and the Group's actual future financial condition, performance and results may differ materially from the plans, goals and expectations set out in the forward-looking statements in this announcement. The Group undertakes no obligation to update any of the forward-looking statements contained within this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDVLBLLFLBBBD
Date   Source Headline
24th Feb 20262:25 pmRNSChange of Company Name
18th Feb 20262:12 pmRNSAppointment of Corporate Broker
6th Feb 20261:52 pmRNSDirector/PDMR Shareholding
2nd Feb 202611:02 amRNSTotal Voting Rights
6th Jan 20261:31 pmRNSDirector/PDMR Shareholding
2nd Jan 202611:06 amRNSTotal Voting Rights
18th Dec 20252:38 pmRNSCompletion of Redemption at Maturity
18th Dec 20252:38 pmRNSCompletion of Redemption at Maturity
12th Dec 20252:49 pmRNSBlock listing Return
8th Dec 202511:08 amRNSDirector/PDMR Shareholding
1st Dec 20251:57 pmRNSTotal Voting Rights
24th Nov 20255:20 pmRNSBlock Listing Application
24th Nov 20257:09 amRNSLIST 2025 Results Show Robust Capital Position
6th Nov 20253:47 pmRNSDirector/PDMR Shareholding
3rd Nov 202512:01 pmRNSTotal Voting Rights
31st Oct 20253:10 pmRNSDirector/PDMR Shareholding
7th Oct 20251:20 pmRNSDirector/PDMR Shareholding
1st Oct 202512:38 pmRNSTotal Voting Rights
17th Sep 20252:40 pmRNSPublication of a Supplementary Prospectus
10th Sep 20252:51 pmRNSDirector/PDMR Shareholding
8th Sep 20255:23 pmRNSDirector/PDMR Shareholding
8th Sep 20257:00 amRNS2025 Interim Results
1st Sep 202510:00 amRNSTotal Voting Rights
18th Aug 202510:00 amRNSBoard Changes
6th Aug 202512:53 pmRNSDirector/PDMR Shareholding
1st Aug 202510:18 amRNSTotal Voting Rights
8th Jul 20253:31 pmRNSDirector/PDMR Shareholding
1st Jul 202512:26 pmRNSTotal Voting Rights
26th Jun 20259:00 amRNSBoard Changes
13th Jun 20253:00 pmRNSPublication of Prospectus
12th Jun 20252:43 pmRNSBlock listing Return
9th Jun 202512:25 pmRNSDirector/PDMR Shareholding
2nd Jun 202512:44 pmRNSTotal Voting Rights
23rd May 20253:02 pmRNSDirector/PDMR Shareholding
20th May 202510:00 amRNSDirector Declaration
13th May 20253:34 pmRNSResult of AGM
7th May 20254:20 pmRNSDirector/PDMR Shareholding
1st May 202510:33 amRNSTotal Voting Rights
10th Apr 20252:37 pmRNSDirector/PDMR Shareholding
8th Apr 20253:10 pmRNSDirector/PDMR Shareholding
3rd Apr 20251:35 pmRNSNotice of AGM
1st Apr 20252:52 pmRNSDirector/PDMR Shareholding
1st Apr 20252:42 pmRNSTotal Voting Rights
26th Mar 20253:46 pmRNSDirector/PDMR Shareholding
24th Mar 20255:43 pmRNSDirector/PDMR Shareholding
21st Mar 202511:56 amRNSDirector/PDMR Shareholding
20th Mar 20254:19 pmRNSDirector/PDMR Shareholding
19th Mar 20254:26 pmRNSDirector/PDMR Shareholding
19th Mar 20252:15 pmRNSDirector/PDMR Shareholding
17th Mar 20257:00 amRNS2024 Annual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.